Use of different parameters and equations for calculation of IC 50 values in efflux assays: Potential sources of variability in IC50 determination

AAPS Journal

Volumn 16, Issue 1, 2014, Pages 172-180

  Volpe, Donna A ^a   Hamed, Salaheldin S ^a   Zhang, Lei K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Caco 2; Drug interaction; IC50; Inhibition; P glycoprotein

Indexed keywords

DIGOXIN; ITRACONAZOLE; SPIRONOLACTONE; VARDENAFIL;

ARTICLE; CELL ASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG INHIBITION; DRUG PENETRATION; DRUG POTENCY; DRUG TRANSPORT; IC 50; IN VITRO STUDY; MATHEMATICAL COMPUTING;

ALGORITHMS; CACO-2 CELLS; CARDIOTONIC AGENTS; DIGOXIN; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; ITRACONAZOLE; PIPERAZINES; SPIRONOLACTONE; SULFONES; TRIAZINES;

EID: 84893688044     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9554-7     Document Type: Article

References (57)

1. Balimane PV, Marino A, Chong S. P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? AAPS J. 2008;10:577-86.
2. Food and Drug Administration (2012). Draft guidance. Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Available from http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm. Accessed 28 October 2013.
3. European Medicine Agency. Guideline on the investigation of drug interactions. 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/ document/document-detail.jsp? webContentId=WC500129606&mid= WC0b01ac058009a3dc. Accessed 28 October 2013.
4. Han HK. Role of transporters in drug interactions. Arch Pharmacol Res. 2011;34:1865-77.
5. Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006; 8(1):article 1.
6. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006;27:543-54.
7. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationships between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408-14.
8. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001;299:620-8.
9. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drugdigoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci. 2005;26:386-93.
10. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci. 2008;97:712-25.
11. Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos. 2005;33:1679-87.
12. Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, et al. Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin DDI risk assessment decision criteria. Drug Metab Dispos. 2013;41:1347-66.
13. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, et al. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci. 2011;100:4013-23.
14. Taur JS, Rodriguez-Proteau R. Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica. 2008;38:1536-50.
15. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica. 2008;38:709-24.
16. Zhang L, Zhang Y, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11:300-6.
17. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, et al. Drug-drug interactions mediated through Pglycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85:173-81.
18. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006;34:786-92.
19. 50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm. 2010;7:398-411.
20. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
21. Gheorghiade M, Adams KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959-64.
22. Nakamura T, Kakumoto M, Yamashita K, Takara K, Tanigawara Y, Sakaeda T, et al. Factors influencing the prediction of steady state concentrations of digoxin. Biol Pharm Bull. 2001;24:403-8.
23. Fenster PE, Hager WD, Goodman MM. Digoxin-quinidine-spironolactone interaction. Clin Pharmacol Ther. 1984;36:70-3.
24. Hedman A, Angelin B, Arvidsson A, Dahlqvist R. Digoxininteractions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol. 1992;42:481-5.
25. Waldorff S, Andersen JD, Heebøll-Nielsen N, Nielsen OG, Moltke E, Sørensen U, et al. Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther. 1978;24:162-7.
26. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G. Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol Renal Physiol. 1999;277:F84-96.
27. Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model. Pharmacother. 2003;23:436-42.
28. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999;22:1355-9.
29. Saad AH, De Pestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730-44.
30. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30:842-54.
31. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit. 1997;19:609-13.
32. Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol. 1996;79:274-6.
33. Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 2011;6:e19329.
34. Shi Z, Tiwari AK, Patel AS, Fu LW, Chen ZS. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res. 2011;71:3735-8.
35. Jian-Wei D, Song I, Shon J, Shin J. Characterization of efflux transport of PDE5 inhibitors, sildenafil, vardenafil, and udenafil. Clin Pharmacol Ther. 2009;85 Suppl 1:S49.
36. Choi MK, Song IS. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. J Pharm Pharmacol. 2012;64:1074-83.
37. Rohde G, Bauer R-J, Unger S, Ahr G, Wensing G. Vardenafil, a new selective PDE5 inhibitor, produces no interaction with digoxin. Pharmacotherapy. 2001;21:1254.
38. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002;19:765-72.
39. Glavinas H, von Richter O, Vojnits K, Mehn D, Nagy T, Janossy J, et al. Calcein assay: a high-throughput method to assess P-gp inhibition. Xenobiotica. 2011;41:712-9.
40. Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, et al. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastineinduced Caco-2 cell lines. Eur J Pharm Biopharm. 2007;67:548-54.
41. Kamiyama E, Sugiyama D, Nakai D, Miura S, Okazaki O. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. Drug Metab Dipos. 2009;37:1956-62.
42. Mease K, Sane R, Podila L, Taub ME. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012;101:1888-97.
43. Patil AG, D'Souza R, Dixit N, Damre A. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. Eur J Drug Metab Pharmacokinet. 2011;36:115-9.
44. Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2008;97:553-65.
45. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci. 2008;35:383-96.
46. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011;39:1196-202.
47. Darnell M, Karlsson JE, Owen A, Hidalgo IJ, Li J, Zhang W, et al. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. Drug Metab Dispos. 2010;38:491-7.
48. Elsby R, Surry DD, Smith VN, Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of Pglycoprotein to support regulatory submissions. Xenobiotica. 2008;38:1140-64.
49. Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci. 2010;86:52-8.
50. Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011;39:275-82.
51. Perloff ES, Mason AK, Kapadnis S, Khun W, Fox LG, Stresser DM. Comparison of digoxin efflux inhibition in Caco-2 and MDR1-LLC-PK1 cell monolayers. Drug Metab Rev. 2011;43 Suppl 2:193.
52. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, et al. Role of P-glycoprotein inhibition for drug interactions evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46:1039-49.
53. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28:655-60.
54. von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn-Schmied Arch Pharmacol. 2009;379:11-26.
55. Hsiao P, Bui T, Ho RJY, Unadkat JD. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos. 2008;36:481-4.
56. Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F2 values. Drug Metab Dispos. 2006;34:203-7.
57. app values vs. efflux ratios. Drug Metab Rev. 2009;41 Suppl 3:76.